Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine

Schizophrenia Research

Volumn 106, Issue 2-3, 2008, Pages 300-307

  Newcomer, John W ^a   Meyer, Jonathan M ^b   Baker, Ross A ^c   Eudicone, James M ^c   Pikalov, Andrei ^d   Vester Blokland, Estelle ^c   McQuade, Robert D ^d   Crandall, David T ^c   Carson, William H ^d   Marcus, Ronald N ^e   L'Italien, Gilbert ^e,f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Non high density lipoprotein cholesterol; Olanzapine; Triglyceride

Indexed keywords

ARIPIPRAZOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLESTEROL; CHOLESTEROL, HDL; ENDPOINT DETERMINATION; FEMALE; HUMANS; LIPOPROTEINS; MALE; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 56149105939     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.09.002     Document Type: Article

References (43)

1. ADA/APA/AACE/NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 27 2 (2004) 596-601
2. Allison B.D., Mentore L.J., Heo M., Chandler P.L., Cappelleri C.J., Infante C.M., and Weiden J.P. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 11 (1999) 1686-1696
3. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 1 (2002) 381-389
4. Chrzanowski W.K., Marcus R.N., Torbeyns A., Nyilas M., and McQuade R.D. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 189 2 (2006) 259-266
5. Citrome L. Olanzapine: interpreting the label change. Int. J. Clin. Pract. 61 12 (2007) 1960-1962
6. Colton C.W., and Manderscheid R.W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis. 3 2 (2006) A42
7. Fagiolini A., Frank E., Scott J.A., Turkin S., and Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 7 5 (2005) 424-430
8. Farwell W.R., Sesso H.D., Buring J.E., and Gaziano J.M. Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am. J. Cardiol. 96 8 (2005) 1129-1134
9. Fleischhacker, W.W., McQuade, R.D., Marcus, R.N., Archibald, D., Swanink, R., Carson, W.H., in press. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol. Psychiatry.
10. Frontini M.G., Srinivasan S.R., Xu J.H., Tang R., Bond M.G., and Berenson G. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am. J. Cardiol. 100 1 (2007) 64-68
11. Gardner C.D., Winkleby M.A., and Fortmann S.P. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994). Am. J. Cardiol. 86 3 (2000) 299-304
12. Goff D.C., Sullivan L., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G., Lamberti S., D'Agnostin o R.B., Stroup T.S., and Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophr. Res. 80 1 (2005) 45-53
13. Grundy S.M., Cleeman J.I., Merz C.N.B., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
14. Jeppesen J., Hein H.O., Suadicani P., and Gyntelberg F. High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. Am. Heart J. 145 1 (2003) 103-108
15. Jiang R., Schulze M.B., Li T., Rifai N., Stampfer M.J., Rimm E.B., and Hu F.B. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27 8 (2004) 1991-1997
16. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur. J. Pharmacol. 441 3 (2002) 137-140
17. Keck Jr. P.E., and McElroy S.L. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin. Investig. Drugs 12 4 (2003) 655-662
18. Koro C.E., Fedder D.O., L'Italien G.J., Weiss S., Magder L.S., Kreyenbuhl J., Revicki D., and Buchanan R.W. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch. Gen. Psychiatry 59 11 (2002) 1021-1026
19. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
20. L'Italien G.J., Casey D.E., Kan H.J., Carson W.H., and Marcus R.N. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J. Clin. Psychiatry 68 10 (2007) 1510-1516
21. Liu J., Sempos C.T., Donahue R.P., Dorn J., Trevisan M., and Grundy S.M. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am. J. Cardiol. 98 10 (2006) 1363-1368
22. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., and Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
23. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., and Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 139 10 (2003) 802-809
24. McLaughlin T., Reaven G., Abbasi F., Lamendola C., Saad M., Waters D., Simon J., and Krauss R.M. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am. J. Cardiol. 96 3 (2005) 399-404
25. McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., Archibald D., and Carson W.H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65 Suppl. 18 (2004) 47-56
26. Meyer J.M., and Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70 1 (2004) 1-17
27. Meyer J.M., Davis V.G., Goff D.C., McEvoy J.P., Nasrallah H.A., Davis S.M., Rosenheck R.A., Daumit G.L., Hsiao J., Swartz M.S., Stroup T.S., and Lieberman J.A. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr. Res. 101 1-3 (2008) 273-286 (2008 Apr), (Epub 2008 Feb 6)
28. Morrato E.H., Newcomer J.W., Allen R.R., and Valuck R.J. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry 69 2 (2008) 316-322
29. Nasrallah H.A. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr. 11 7 Suppl 7 (2006) 32-39
30. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., and Lieberman J.A. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 86 1-3 (2006) 15-22
31. NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 19 (2001) 2486-2497
32. Newcomer J.W. Metabolic risk during antipsychotic treatment. Clin. Ther. 26 12 (2004) 1936-1946
33. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
34. Newcomer J.W., and Hennekens C.H. Severe mental illness and risk of cardiovascular disease. JAMA 298 15 (2007) 1794-1796
35. Newcomer J.W., Campos J.A., Marcus R.N., Breder C., Berman R.M., Kerselaers W., l'Italian G., Kaplita S., Carson W.H., and McQuade R.D. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J. Clin. Psychiatry 69 7 (2008) 1046-1056 (Jul)
36. Sattar N., Williams K., Sniderman A.D., D'Agostino Jr. R., and Haffner S.M. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 110 17 (2004) 2687-2693
37. Schulze M.B., Shai I., Manson J.E., Li T., Rifai N., Jiang R., and Hu F.B. Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes. Diabetologia 47 12 (2004) 2129-2136
38. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 8 (2003) 1400-1411
39. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., and Hsiao J.K. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163 4 (2006) 611-622
40. Stroup T.S., McEvoy J.P., Swartz M.S., Hamer R.M., Perkins D.O., and Lieberman J.A. Comparison of antipsychotics for metabolic problems (CAMP): a NIMH Schizophrenia Trials Network study. Clin. Schizophr. Relat. Psychoses (2007) 69-72 April
41. Weiden P.J., Daniel D.G., Simpson G., and Romano S.J. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J. Clin. Psychopharmacol. 23 6 (2003) 595-600
42. Weiden P.J., Newcomer J.W., Loebel A.D., Yang R., and Lebovitz H.E. Long-term changes in weight and plasma lipids during maintenance treatment with Ziprasidone. Neuropsychopharmacology 33 5 (2008) 985-994
43. Zyprexa. Eli Lilly and Company. Zyprexa (olanzapine) Prescribing Information (2008), Eli Lilly and Company, Indianapolis, IN, USA